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ABSTRACT
Objective To compare the performance of the EuroQol 5D 
youth (EQ- 5D- Y) and child health utility 9D (CHU- 9D) for 
assessing health- related quality of life (HRQoL) in children 
and young people (CYP) with cerebral palsy (CP).
Design Cross- sectional study.
Setting England.
Participants Sixty- four CYP with CP aged 10–19 years 
in Gross Motor Function Classification System (GMFCS) 
levels I–III.
Main outcome measures Missing data were examined to 
assess feasibility. Associations between utility values and 
individual dimensions on each instrument were examined 
to assess convergent validity. Associations between utility 
values and GMFCS level were examined to assess known- 
group differences.
Results Missing data were <5% for both instruments. 
Twenty participants (32.3%) and 11 participants 
(18.0%) reported full health for the EQ- 5D- Y and CHU- 
9D, respectively. There was poor agreement between 
utilities from the two instruments (intraclass correlation 
coefficient=0.62; 95% limits of agreement −0.58 to 0.29). 
Correlations between EQ- 5D- Y and CHU- 9D dimensions 
were weak to moderate (r=0.25 to 0.59). GMFCS level was 
associated with EQ- 5D- Y utility values but not CHU- 9D 
utility values.
Conclusion The EQ- 5D- Y and CHU- 9D are feasible 
measures of HRQoL in CYP with CP. However, the two 
instruments demonstrate poor agreement and should 
not be used to measure and value HRQoL in CYP with CP 
interchangeably. We propose that the CHU- 9D may be 
preferable to use in this population as it assesses concepts 
that influence HRQoL among CYP with CP and provides 
less extreme utility values than the EQ- 5D- Y.
INTRODUCTION
Cerebral palsy (CP) is a heterogeneous 
disorder characterised by abnormal move-
ment and posture. It is often coexistent with 
epilepsy, intellectual disability and language, 
communication or behavioural difficulties.1 
Its prevalence is 2/1000 live births2 ; approxi-
mately 110 000 people live with CP in the UK.3 
CP is a lifelong condition. Management of CP 
encompasses medical, surgical and rehabilita-
tion interventions.1 While a large volume of 
research has examined the effectiveness of 
interventions for people with CP,4 there is 
limited research examining cost- effectiveness 
of such interventions.
Economic evaluation is used to inform the 
efficient allocation of resources in a health-
care setting. The cost utility analysis (CUA) 
is the type of economic evaluation recom-
mended by the National Institute for Health 
and Care Excellence particularly for inter-
ventions funded by National Health Service 
(NHS) and personal social services.5 The 
CUA commonly describes the relationship 
between costs and health benefits as the cost 
per quality- adjusted life year (QALY). QALYs 
incorporate both quantity and quality of life. 
QALYs are commonly calculated using an 
assessment of health- related quality of life 
(HRQoL) obtained from a preference- based 
instrument. Such instruments can provide a 
health state utility value, where 0 indicates a 
health state of equivalent value to being dead 
and 1.0 indicates full health, by applying 
a prespecified algorithm based on prefer-
ences for health status identified in a specific 
population.6
Generic HRQoL instruments are recom-
mended for use in economic evaluations 
as they allow comparison across healthcare 
Strengths and limitations of this study
 ► This is the first study to compare the performance of 
the EuroQol 5D youth and child health utility 9D in a 
clinical population.
 ► Children and young people were recruited from the 
National Health Service, education and disability or-
ganisations across England.
 ► The findings are limited by a small sample and by 
inclusion of ambulatory individuals only.
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interventions and populations. However, if scores from 
generic measures differ, estimates of cost- effectiveness will 
be impacted, leading to uncertain conclusions regarding 
whether an intervention provides value for money. A 
number of generic measures have been used to obtain 
health state utility values from paediatric populations.7 
The most commonly used are the EuroQol 5D (EQ- 5D), 
the child health utility 9D (CHU- 9D), the EQ- 5D youth 
(EQ- 5D- Y) and the Health Utilities Index 2 and 3 (HUI-2 
and HUI-3).7 To date, however, only the HUI-2 and HUI-3 
have been used to elicit utility values from children and 
young people (CYP) with CP and significant variation was 
reported in these.8
The EQ- 5D- Y and CHU- 9D are two generic preference- 
based HRQoL instruments that were designed specifi-
cally for young people. The EQ- 5D- Y is a youth- modified 
version of the adult instrument, the EQ- 5D, which was 
developed by revising the content and wording of the 
adult instrument.9 The CHU- 9D was developed from the 
outset for young people based on in- depth interviews with 
young people with chronic and acute health conditions.10 
Although the performance of the EQ- 5D- Y and CHU- 9D 
has been examined in an adolescent population,11 their 
performance has not been examined among CYP with CP.
Given the financial cost of CP per annum is approxi-
mately AU$1.5 billion12 and a wide range of interventions 
are currently available for people with CP,4 there is an 
increasing need for economic evaluation in this area. Prior 
to conducting economic evaluations, the performance of 
the EQ- 5D- Y and CHU- 9D in CYP with CP requires eval-
uation. The aim of this study was to compare the perfor-
mance of the EQ- 5D- Y and CHU- 9D for assessing HRQoL 
in a community- based sample of CYP with CP. Specific 
objectives were to examine the feasibility of administering 
the instruments, to examine convergent validity and to 
examine known- group differences for both instruments.
METHODS
Sample
CYP with CP who participated in a randomised controlled 
trial examining the effects of progressive resistance 
training were included in this study.13 Data collected at 
baseline were used for this cross- sectional study. Partici-
pants were recruited from eight NHS trusts in England, 
a special education needs school, a university and a 
primary care organisation in London, national organisa-
tions for people with disabilities, and by word of mouth. 
Inclusion criteria for participation in the trial were: aged 
10–19 years with spastic CP and the ability to walk inde-
pendently with or without a mobility aid (ie, Gross Motor 
Function Classification System (GMFCS) levels I–III). 
Exclusion criteria for participation in the trial were ortho-
paedic surgery of the lower limbs in the past 12 months, 
botulinum toxin type A injections or serial casting in the 
past 6 months and insufficient cognition to comply with 
assessment procedures and the training programme. 
Participants 16 years and older provided written consent. 
Those under 16 years provided assent alongside written 
consent from a parent or guardian.
Data on the person’s demographics, condition and 
HRQoL were collected using standardised questionnaires 
during an interview with a researcher at one time point. 
Both HRQoL questionnaires were self- administered to all 
participants using the standardised instructions accom-
panying each instrument. Assistance was provided by the 
researcher to read the questions if required. Further, the 
young person was allowed to ask their parent/guardian 
or researcher for assistance to answer the questions 
if required. Anatomical distribution was described as 
unilateral or bilateral.14 Functional mobility was classified 
according to the GMFCS. The GMFCS is a five- level clas-
sification system, where level I indicates most able and 
level V indicates most limited. Those in GMFCS level I are 
able to walk and run and climb stairs without assistance. 
Those in level II are able to walk in most settings but 
may use a hand- held mobility device indoors or wheeled 
mobility to travel long distances. Those in level III can 
walk using a hand- held mobility device but use a wheel-
chair or powered mobility outdoors. Participants selected 
a statement that best described their mobility based on 
descriptors of each GMFCS level.15 Two physiothera-
pists retrospectively cross- referenced subjective ratings 
of GMFCS level against video recordings of participants, 
obtained as part of the baseline assessment.
Utility measurement
The EQ- 5D- Y assesses a person’s health across five dimen-
sions. The five dimensions are ‘mobility’, ‘looking after 
myself’, ‘doing usual activities’, ‘having pain or discom-
fort’ and ‘feeling worried, sad or unhappy’.9 Each dimen-
sion is rated on one of three levels (no problems, some 
problems and a lot of problems) that describes a person’s 
health today.9 The EQ- 5D- Y was developed by reviewing 
the applicability of the EQ- 5D domain concepts and 
wording for children and adolescents.9 The EQ- 5D- Y is 
suitable for use in young people aged 8–19 years.16 At 
present, there is no value set for the EQ- 5D- Y. Although 
use of the adult value set (EQ- 5D) for the EQ- 5D- Y is not 
recommended, we calculated utilities using UK- based 
adult weights.17 We acknowledge the limitation of this, 
but considered it to be the best method given the lack 
of weights for the EQ- 5D- Y. Further, although the perfor-
mance of the EQ- 5D- Y using the adult value set has been 
examined in CYP with typical development,18 it has not 
been examined in a clinical population.
There are nine dimensions in the CHU- 9D: ‘worried’, 
‘sad’, ‘pain’, ‘tired’, ‘annoyed’, ‘schoolwork’, ‘sleep’, 
‘daily routine’ and ‘ability to join in activities’.10 For 
each dimension, the person describes how they are today 
according to one of five levels based on severity (eg, not 
worried, a little bit worried, a bit worried, quite worried, 
very worried), which were determined from in- depth 
interviews with young people.10 The CHU- 9D is suit-
able for use in young people aged 7–17 years.10 19 The 
scoring algorithm based on the preferences of the UK 
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adult general population was used to estimate utilities.20 
This method has been shown to be appropriate to use for 
young people.18
Patient and public involvement
CYP with and without CP were involved in the design, 
conduct and dissemination plans of our research relating 
to the randomised controlled trial examining the effects 
of progressive resistance training.
Statistical analysis
The distribution of data was examined using histograms, 
Q–Q plots and cross- tabulations. Mean and SD, median 
and IQR, frequencies and percentages were used to 
report the data as appropriate. We examined feasibility by 
reporting the number of participants with missing data 
and the percentage of missing data for each instrument. 
The instrument was considered feasible if missing data 
were <5%.21 Participants who were missing data for an 
individual dimension of the EQ- 5D- Y or CHU- 9D were 
excluded from the calculation of utility values and from 
analyses involving that dimension.
To assess convergent validity, we calculated an intra-
class correlation coefficient (ICC) between CHU- 9D 
and EQ- 5D- Y utility values. We interpreted an ICC >0.75 
as indicating good agreement.22 We compared mean 
utility between instruments using linear regression with 
a bootstrap procedure as there was evidence that resid-
uals were not normally distributed. Bias corrected and 
accelerated bootstrap CIs were calculated from 2000 
replicates.23 We also produced a Bland- Altman plot of 
the difference between the two instruments against their 
mean to examine agreement between utilities from the 
two instruments. We calculated 95% limits of agreement 
as mean difference ±1.96 SD.24 We examined the associa-
tion between (1) CHU- 9D utility value and levels of each 
EQ- 5D- Y dimension and (2) EQ- 5D- Y utility value and levels 
of each CHU- 9D dimension, by calculating Spearman’s 
correlation coefficients. We also examined associations 
between each dimension of the EQ- 5D- Y and CHU- 9D 
by calculating Spearman’s correlation coefficients. Based 
on the description of each dimension and associations 
observed among adolescents with typical development,11 
we hypothesised that the following dimensions would be 
correlated between the CHU- 9D and EQ- 5D- Y, respec-
tively: ‘worried’ versus ‘feeling worried, sad or unhappy’, 
‘sad’ versus ‘feeling worried, sad or unhappy’, ‘pain’ 
versus ‘having pain/discomfort’, ‘daily routine’ versus 
‘doing usual activities’, ‘daily routine’ versus ‘looking 
after myself’, ‘able to join in’ versus ‘doing usual activi-
ties’ and ‘able to join in’ versus ‘mobility’. To aid interpre-
tation, we proposed a correlation of 0.10–0.39 to indicate 
a weak association, a correlation of 0.40–0.75 to indicate 
a moderate association and a correlation of >0.75 to indi-
cate a strong association.22 25 However, this interpretation 
should be used with caution given that cut- offs for inter-
preting correlation coefficients are arbitrary and may be 
inconsistent with other studies.25
We examined known- group differences by fitting 
linear regression models using a bootstrap procedure 
to compare CHU- 9D utility values and EQ- 5D- Y utility 
values, respectively, across functional mobility as defined 
by the GMFCS. A bootstrap procedure was used as there 
was evidence that residuals were not normally distributed. 
For each model, utility value was the dependent variable 
and bias corrected and accelerated bootstrap CIs were 
calculated from 2000 replicates.23 We also compared 
the number of people experiencing no problems versus 
any problems for each CHU- 9D and EQ- 5D- Y dimension 
across GMFCS level, using a χ2 test. It was expected that 
CYP with better functional mobility would have higher 
utilities.26 27 MedCalc V.19.2.0 was used to produce the 
Bland- Altman plot. All other statistical analyses were 
performed using Stata V.13.
RESULTS
Sixty- four participants were recruited to the study. One 
person did not complete the EQ- 5D- Y or CHU- 9D. 
Therefore, 63 participants were included in the analysis. 
Table 1 describes the participant characteristics. The 
mean±SD age was 13.7±2.5 years. The majority of partici-
pants (86%) was in GMFCS levels I or II indicating a mild 
lower limb impairment. The majority of participants was 
White British (59%) and attended a mainstream school 
(71%).
For the EQ- 5D- Y, one participant did not provide a 
response to the ‘looking after myself’ dimension. For the 
CHU- 9D, two participants did not provide a response to 
the schoolwork dimension and one participant did not 
provide a response to the ability to ‘join in activities’ 
dimension. Utility values for the EQ- 5D- Y were there-
fore calculated for 62 out of 64 participants (96.9%) and 
utility values for the CHU- 9D were calculated for 61 out of 
64 participants (95.3%). Missing data were 1.9% for the 
EQ- 5D- Y and 2.0% for the CHU- 9D.
The distribution of EQ- 5D- Y and CHU- 9D utilities is 
shown in figures 1 and 2. For the EQ- 5D- Y and CHU- 9D, 
respectively, 20 participants (32.3%) and 11 participants 
(18.0%) reported full health. The median (IQR) EQ- 5D- Y 
utility value was 0.80 (0.62–1.00). The mean±SD EQ- 5D- Y 
utility value was 0.73±0.29 (range −0.17 to 1.00). Two 
participants (3.2%) reported a ‘worse than death’ health 
state for the EQ- 5D- Y. The median (IQR) CHU- 9D utility 
value was 0.92 (0.83–0.96). The mean±SD CHU- 9D utility 
value was 0.89±0.10 (range 0.56–1.00). There was poor 
agreement between utilities from the two instruments as 
indicated by an ICC of 0.62. The CHU- 9D utility value was 
on average 0.15 (95% CI 0.09 to 0.25) higher than the 
EQ- 5D- Y utility value. 95% limits of agreement were −0.58 
to 0.29, indicating that the EQ- 5D- Y utility value may be 
0.29 higher or 0.58 lower than the CHU- 9D utility value 
(figure 3).
The percentages of reported problems across dimen-
sions of the EQ- 5D- Y and CHU- 9D are presented in 
tables 2 and 3. There was evidence of correlation between 
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Table 1 Participant characteristics
n (%) Mean (SD) Range
Mean (SD)
EQ- 5D- Y
utility value
Median (IQR)
EQ- 5D- Y
utility value
Mean (SD)
CHU- 9D
utility value
Median (IQR)
CHU- 9D
utility value
Age, years 63 13.7 (2.5) 10–19 – – – –
Female 26 (41.3) 0.77 (0.29) 0.83 (0.69–1.00) 0.90 (0.08) 0.92 (0.83–0.97)
Male 37 (58.7) 0.71 (0.29) 0.77 (0.62–0.93) 0.88 (0.11) 0.92 (0.81–0.95)
Height, cm 63 154.3 (12.7) 131.5–180.9 – – – –
Mass, kg 63 49.3 (13.7) 27.4–78.5 – – – –
Ethnicity
  White British 37 (58.7) 0.80 (0.20) 0.81 (0.69–1.00) 0.89 (0.09) 0.92 (0.84–0.95)
  Black or Black 
British
5 (7.9) 0.62 (0.44) 0.81 (0.19–1.00) 0.90 (0.10) 0.90 (0.81–1.00)
  Asian or Asian 
British
9 (14.3) 0.59 (0.49) 0.73 (0.20–1.00) 0.88 (0.12) 0.92 (0.89–0.95)
  Other 12 (19.0) 0.69 (0.22) 0.75 (0.57–0.81) 0.87 (0.13) 0.87 (0.82–0.97)
GMFCS level
  I 29 (46.0) 0.82 (0.20) 0.81 (0.73–1.00) 0.89 (0.11) 0.92 (0.82–0.95)
  II 25 (39.7) 0.75 (0.25) 0.75 (0.62–1.00) 0.90 (0.08) 0.92 (0.86–0.97)
  III 9 (14.3) 0.39 (0.43) 0.44 (0.00–0.76) 0.82 (0.12) 0.83 (0.72–0.89)
Distribution
  Unilateral 31 (49.2) 0.81 (0.18) 0.80 (0.69–1.00) 0.91 (0.09) 0.92 (0.87–0.98)
  Bilateral 32 (50.8) 0.66 (0.35) 0.75 (0.59–1.00) 0.87 (0.11) 0.87 (0.81–0.95)
Type of school
  Mainstream 
school
45 (71.4) 0.77 (0.24) 0.80 (0.67–1.00) 0.88 (0.08) 0.90 (0.82–0.95)
  SEN 13 (20.6) 0.62 (0.41) 0.80 (0.44–0.85) 0.89 (0.11) 0.92 (0.86–0.98)
  Further college 
education
2 (3.2) 0.85 (0.22) 0.85 (0.69–1.00) 0.99 (0.01) 0.99 (0.98–1.00)
  University 3 (4.8) 0.67 (0.45) 0.85 (0.16–1.00) 0.85 (0.25) 1.00 (0.56–1.00)
CHU- 9D, child health utility 9D; EQ- 5D- Y, EuroQol 5D youth; GMFCS, gross motor function classification system; SEN, special education 
needs.
Figure 1 Distribution of utility values for the EuroQol 5D 
youth (EQ- 5D- Y).
Figure 2 Distribution of utility values for the child health 
utility 9D (CHU- 9D).
 o
n
 Septem
ber 16, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-037089 on 10 September 2020. Downloaded from 
5Ryan JM, et al. BMJ Open 2020;10:e037089. doi:10.1136/bmjopen-2020-037089
Open access
EQ- 5D- Y utility values and level of severity for all dimen-
sions of the CHU- 9D except for the ‘sad’ dimension. 
Correlations ranged from −0.12 to −0.64 (table 2). For 
all dimensions of the EQ- 5D- Y, the median CHU- 9D 
utility value decreased with increasing levels of severity 
on the EQ- 5D- Y dimensions (table 3). For all dimensions 
of the EQ- 5D- Y, the majority of respondents reported 
themselves in the least severe level (ie, no problems). 
However, responses for most dimensions of the EQ- 5D- Y 
were spread across all levels, from no problems to a lot 
of problems. The exception to this was the ‘worried, sad 
or unhappy’ dimension; no participant reported feeling 
very worried, sad or unhappy. Similarly, for all dimen-
sions of the CHU- 9D except for ‘tired’, the majority of 
participants reported themselves in the least severe level. 
However, responses were not spread across all levels 
for each dimension. For the ‘worried’, ‘sad’, ‘pain’, 
‘annoyed’, ‘sleep’ and ‘daily routine’ dimensions of the 
CHU- 9D, no participant reported the most severe level.
Correlations between CHU- 9D and EQ- 5D- Y dimen-
sions are presented in table 4. Moderate correlations 
(r=0.43–0.59) were observed for all hypothesised associa-
tions, except for ‘worried’ versus ‘feeling worried, sad or 
unhappy’ (r=0.25) and ‘daily routine’ versus ‘doing usual 
activities’ (r=0.35). Several unexpected correlations were 
observed between dimensions. Namely, ‘schoolwork’ 
on the CHU- 9D was associated with ‘mobility’ (r=0.56), 
‘pain or discomfort’ (r=0.55) and ‘doing usual activities’ 
(r=0.44) on the EQ- 5D- Y; ‘tired’ on the CHU- 9D was asso-
ciated with ‘pain/discomfort’ on the EQ- 5D- Y (r=0.40) 
and ‘annoyed’ on the CHU- 9D was associated with 
‘worried/sad/unhappy’ on the EQ- 5D- Y (r=0.53).
Median (IQR) utilities by GMFCS level are presented in 
table 1. EQ- 5D- Y utility value was associated with GMFCS 
level (R2=0.231, p=0.016; online supplemental table 1). 
As expected, EQ- 5D- Y utility value was on average 0.43 
lower in individuals in level III compared with those in 
level I (95% CI 0.14 to 0.73) and 0.36 lower in individ-
uals in level III compared with those in level II (95% CI 
0.06 to 0.66). However, there was no difference in utility 
value between those in levels I and II. Although median 
CHU- 9D utility value was lower in GMFCS level III 
compared with GMFCS levels I and II (table 1), there was 
no evidence that CHU- 9D utility value was associated with 
GMFCS level (R2=0.071, p=0.170; online supplemental 
table 2). As presented in table 5, the percentage of people 
reporting some or a lot of problems on the ‘mobility’ and 
‘looking after myself’ dimensions of the EQ- 5D- Y differed 
according to GMFCS level, with the percentage of people 
reporting problems increasing from GMFCS levels I to 
III. The percentage of people reporting problems was 
not associated with GMFCS level for any other EQ- 5D- Y 
dimension. There was also no evidence of an association 
between the percentage of people reporting problems 
and GMFCS level for any dimension of the CHU- 9D 
(table 6).
DISCUSSION
The aim of this study was to compare the performance of 
the EQ- 5D- Y and CHU- 9D for assessing HRQoL in CYP 
with CP. Specific objectives were to examine feasibility, 
convergent validity and known- group differences. To our 
knowledge, this is the first study to compare the EQ- 5D- Y 
and CHU- 9D in a clinical population. Although the results 
indicate that the two instruments are feasible to use when 
administered by interview to CYP with CP, the two instru-
ments have poor agreement and may not be used inter-
changeably to measure and value HRQoL among CYP 
with CP. The EQ- 5D- Y utility value was on average 0.15 
lower than the CHU- 9D utility value. However, there was 
considerable variation in individual differences between 
instruments. 95% limits of agreement demonstrated that 
the EQ- 5D- Y utility value may be 0.29 higher or 0.58 lower 
than the CHU- 9D utility value for an individual. Addition-
ally, dimensions on each instrument that were hypoth-
esised to measure similar concepts were only weakly to 
moderately associated.
Two studies compared the EQ- 5D- Y and CHU- 9D in 
CYP with typical development.11 18 Agreement between 
EQ- 5D- Y and CHU- 9D utility values was better among 
adolescents with typical development than among 
CYP with CP, with an ICC of 0.80 and much narrower 
95% limits of agreement (−0.268 to 0.241) reported.11 
Although the median EQ- 5D- Y utility value among CYP 
in this study was similar to that reported for Australian 
adolescents with typical development (0.80 vs 0.83), the 
median CHU- 9D utility was higher (0.92 vs 0.83).11 The 
median CHU- 9D utility reported by CYP with CP was more 
similar to that reported by children, aged 6–7 years, with 
typical development living in England (0.92 vs 0.90) and 
the median EQ- 5D- Y utility was identical between these 
groups.18 This may be because the study of children living 
in England used the same algorithms to estimate utilities 
as the current study, while the study of adolescents used 
algorithms developed in the Australian population. It is 
also plausible that CYP with CP have better HRQoL than 
CYP with typical development. A study of a large sample 
of CYP with CP across Europe found that CYP with CP 
Figure 3 Bland- Altman plot of differences between EQ- 
5D- Y and CHU- 9D utility values against average of EQ- 5D- Y 
and CHU- 9D utility values. CHU- 9D, child health utility 9D; 
EQ- 5D- Y, EuroQol 5D youth.
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Table 2 Number and percentage of participants reporting problems across CHU- 9D dimensions
CHU- 9D dimensions Levels Frequency (%) n
Median±IQR
EQ- 5D- Y utility value Rho P value
Worried Not worried 82.5 52 0.81±0.29 −0.38 0.002
A little bit 15.9 10 0.55±0.66
A bit 1.6 1 −0.11
Quite 0 0 –
Very 0 0 –
Sad Not sad 93.7 59 0.80±0.34 −0.12 0.350
A little bit 3.2 2 0.50±0.69
A bit 3.2 2 0.68±0.33
Quite 0 0 –
Very 0 0 –
Pain No pain 61.9 39 0.85±0.29 −0.42 <0.001
A little bit 30.2 19 0.73±0.23
A bit 3.2 2 0.39±0.60
Quite 4.8 3 0.16±0.73
A lot 0 0 –
Tired Not tired 36.5 23 0.82±0.27 −0.44 <0.001
A little bit 42.9 27 0.81±0.31
A bit 9.5 6 0.59±0.07
Quite 7.9 5 0.19±0.46
Very 3.2 2 0.45±0.52
Annoyed Not annoyed 84.1 53 0.81±0.30 −0.27 0.034
A little bit 11.1 7 0.62±0.33
A bit 3.2 2 0.50±0.69
Quite 1.6 1 0.52
Very 0 0 –
Schoolwork/homework
  
No problems 63.5 40 0.93±0.21 −0.64 <0.001
Few problems 17.5 11 0.68±0.10
Some problems 14.3 9 0.55±0.52
Many problems 0 0 –
Can not do 
schoolwork
1.6 1 0.20
Missing 3.2 2 –
Sleep No problems 71.4 45 0.81±0.29 −0.38 0.002
Few problems 20.6 13 0.70±0.24
Some problems 4.8 3 0.73±0.07
Many problems 3.2 2 0.02±0.27
Can not sleep 0 0 –
Daily routine No problems 74.6 47 0.81±0.27 −0.48 <0.001
Few problems 15.9 10 0.52±0.59
Some problems 7.9 5 0.66±0.14
Many problems 1.6 1 0.09
Can not do daily 
routine
0 0 –
Continued
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had better QoL in five domains (moods and emotions, 
self- perception, autonomy, relationships with parents and 
school life) compared with CYP in the general population 
matched for age, sex and country.28
Although the EQ- 5D- Y utility value was on average 
lower than the CHU- 9D utility value, 32% of participants 
reported full health when using the EQ- 5D- Y compared 
with only 18% of participants when using the CHU- 9D. A 
similar ceiling effect for the EQ- 5D- Y was reported among 
CYP with typical development.11 Although a large propor-
tion of CYP had ‘perfect health’ according to the EQ- 5D- Y, 
two children reported a health state worse than death. 
Neither of these children reported the worst possible 
health state according to the CHU- 9D. The CHU- 9D may 
be more sensitive to varying severities of health because 
of the larger number of levels for each dimension. The 
CHU- 9D is also the only generic measure that was specif-
ically designed for CYP and the levels were determined 
from in- depth interviews with young people.10 Further, as 
suggested previously, the extreme health states observed 
for the EQ- 5D- Y may be a result of misapplication of the 
adult EQ- 5D tariff to the health states defined by the 
EQ- 5D- Y.18 The findings from this study provide addi-
tional evidence that the EQ- 5D- Y should not be used to 
measure utilities until a specific value set for the EQ- 5D- Y 
is available.
Although we found associations between a number 
of dimensions on the EQ- 5D- Y and CHU- 9D as hypoth-
esised, these associations were only weak to moderate, 
despite both instruments being administered at the same 
time point, by the same researcher and in the same envi-
ronment. These correlations were weaker than those 
reported among Australian adolescents with typical devel-
opment.11 In particular, the correlation between ‘feeling 
worried, sad or unhappy’ on the EQ- 5D- Y and ‘worried’ 
on the CHU- 9D was 0.70 among adolescents with typical 
CHU- 9D dimensions Levels Frequency (%) n
Median±IQR
EQ- 5D- Y utility value Rho P value
Able to join in activities Any activities 57.1 36 0.85±0.27 −0.43 <0.001
Most activities 27.0 17 0.73±0.23
Some activities 7.9 5 0.60±0.33
Few activities 4.8 3 0.71±0.33
No activities 1.6 1 −0.11
Missing 1.6 1 –
CHU- 9D, child health utility 9D; EQ- 5D- Y, EuroQol 5D youth.
Table 2 Continued
Table 3 Number and percentage of participants reporting problems across EQ- 5D- Y dimensions
EQ- 5D- Y dimensions Levels Frequency (%) n
Median ±IQR
CHU- 9D utility value Rho P value
Mobility No 50.8 32 0.95±0.09 −0.52 <0.001
Some 44.4 28 0.84±0.13
A lot of 4.8 3 0.75±0.05
Looking after myself No 66.7 42 0.94±0.09 −0.46 <0.001
Some 27.0 17 0.83±0.10
A lot of 4.8 3 0.72±0.27
Missing 1.6 1 0.78
Usual activities No 66.7 42 0.93±0.11 −0.54 <0.001
Some 28.6 18 0.83±0.15
A lot of 4.8 3 0.72±0.16
Pain or discomfort No 55.6 35 0.95±0.11 −0.54 <0.001
Some 38.1 24 0.86±0.16
A lot of 6.3 4 0.72±0.24
Worried, sad or
unhappy
Not 84.1 53 0.92±0.11 −0.44 <0.001
A bit 15.9 10 0.79±0.05
Very 0 0 –
CHU- 9D, child health utility 9D; EQ- 5D- Y, EuroQol 5D youth.
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development, compared to 0.25 among CYP with CP. This 
suggests that CYP with CP interpret these two dimensions 
differently and they do not measure the same concept 
in this population. The strongest correlation between 
EQ- 5D- Y and CHU- 9D dimensions among adolescents 
with typical development was between ‘having pain or 
discomfort’ and ‘pain’ (r=0.753).11 However, ‘having 
pain or discomfort’ and ‘pain’ were only moderately 
correlated in CYP with CP (r=0.47). Many CYP with CP 
experience frequent pain,29 and as a result, their interpre-
tation of the EQ- 5D- Y question about pain and discomfort 
may differ to their interpretation of the CHU- 9D question 
about pain only. Indeed, 56% of CYP with CP reported no 
pain or discomfort on the EQ- 5D- Y, while 62% reported 
no pain on the CHU- 9D. Of the hypothesised correla-
tions, only the correlation between ‘looking after myself’ 
on the EQ- 5D- Y and ‘daily routine’ on the CHU- 9D was 
stronger among CYP with CP compared with adolescents 
Table 4 Spearman rank correlation coefficients between CHU- 9D and EQ- 5D- Y dimensions
EQ- 5D- Y dimensions
CHU- 9D dimensions
Worried Sad Pain Tired Annoyed Schoolwork Sleep
Daily 
routine Activities
Mobility r 0.30 −0.01 0.35 0.36 0.19 0.56* 0.31 0.19 0.49†
p 0.017 0.950 0.006 0.004 0.140 <0.001 0.013 0.144 <0.001
Looking after 
myself
r 0.26† −0.04† 0.21† 0.22† 0.08† 0.39‡ 0.27† 0.59† 0.36*
p 0.040 0.741 0.098 0.086 0.525 0.002 0.031 <0.001 0.004
Activities r 0.36 0.08 0.30 0.23 0.25 0.44* 0.38 0.35 0.54†
p 0.004 0.543 0.017 0.065 0.049 <0.001 0.002 0.006 <0.001
Pain or 
discomfort
r 0.33 0.07 0.47 0.40 0.22 0.55* 0.39 0.25 0.32†
p 0.008 0.600 <0.001 0.001 0.090 <0.001 0.002 0.048 0.011
Worried, sad, 
unhappy
r 0.25 0.43 0.19 0.26 0.53 0.39* −0.01 0.33 0.15†
p 0.048 <0.001 0.143 0.039 <0.001 0.002 0.944 0.008 0.239
Correlations with p value<0.05 highlighted in bold; n=63 for all analyses unless stated otherwise.
*n=61.
†n=62.
‡n=60.
CHU- 9D, child health utility 9D; EQ- 5D- Y, EuroQol 5D youth.
Table 5 Percentage reporting problems on each EQ- 5D- Y dimension across GMFCS level
EQ- 5D- Y dimensions Levels
GMFCS level I GMFCS level II GMFCS level III
P value*n=29 n=25 n=9
Mobility No 69% 44% 11% 0.007
Some 31% 56% 56%
A lot of 0% 0% 33%
Looking after myself No 83% 56% 50% 0.036
Some 17% 40% 25%
A lot of 0% 4% 25%
Usual activities No 72% 72% 33% 0.072
Some 28% 24% 44%
A lot of 0% 4% 22%
Pain or discomfort No 59% 60% 33% 0.348
Some 38% 36% 44%
A lot of 3% 4% 22%
Worried, sad or unhappy No 79% 92% 78% 0.380
Some 21% 8% 22%
A lot of 0% 0% 0%
*Comparing number of people experiencing ‘no’ problems versus any problems (ie, some and a lot of) across GMFCS levels.
EQ- 5D- Y, EuroQol 5D youth; GMFCS, Gross Motor Function Classification System.
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Table 6 Percentage reporting problems on each CHU- 9D dimension across GMFCS level
CHU- 9D dimensions Levels
GMFCS level I GMFCS level II GMFCS level III
P value*n=29 n=25 n=9
Worried Not worried 83% 84% 78% 0.914
A little bit 17% 16% 11%
A bit 0% 0% 11%
Quite 0% 0% 0%
Very 0% 0% 0%
Sad Not sad 86% 100% 100% 0.082
A little bit 7% 0% 0%
A bit 7% 0% 0%
Quite 0% 0% 0%
Very 0% 0% 0%
Pain No pain 55% 72% 56% 0.408
A little bit 38% 24% 22%
A bit 0% 4% 11%
Quite 7% 0% 11%
A lot 0% 0% 0%
Tired Not tired 31% 44% 33% 0.601
A little bit 52% 32% 44%
A bit 7% 12% 11%
Quite 10% 8% 0%
Very 0% 4% 11%
Annoyed Not annoyed 72% 96% 89% 0.056
A little bit 17% 4% 11%
A bit 7% 0% 0%
Quite 4% 0% 0%
Very 0% 0% 0%
Schoolwork/homework No problems 72% 64% 43% 0.104
Few problems 17% 16% 29%
Some problems 10% 20% 14%
Many problems 0% 0% 14%
Can not do schoolwork 0% 0% 0%
Sleep Not 79% 68% 56% 0.343
A little bit 10% 28% 33%
A bit 7% 4% 0%
Quite 4% 0% 11%
Very 0% 0% 0%
Daily routine Not 83% 72% 56% 0.243
A little bit 10% 20% 22%
A bit 7% 4% 22%
Quite 0% 4% 0%
Very 0% 0% 0%
Able to join in activities Not 69% 52% 38% 0.135
A little bit 24% 28% 38%
A bit 3.5% 12% 13%
Quite 3.5% 8% 0%
Very 0% 0% 13%
*Comparing number of people experiencing ‘no’ problems versus any problems (ie, a little bit, a bit, quite and very) across GMFCS levels.
CHU- 9D, child health utility 9D; GMFCS, Gross Motor Function Classification System.
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with typical development.11 As the ‘looking after myself’ 
dimension refers specifically to washing and dressing, this 
suggests that CYP with CP interpret self- care as part of 
their daily routine.
We also observed a number of unexpected associations 
between EQ- 5D- Y and CHU- 9D dimensions. ‘School-
work’ on the CHU- 9D was associated with ‘mobility’, 
‘having pain or discomfort’ and ‘doing usual activities’ 
on the EQ- 5D- Y. Approximately 45% of CYP with CP 
have an intellectual disability, which may range from 
mild to severe.30 Although we excluded individuals with 
insufficient cognition to comply with assessment proce-
dures, some participants may have had a mild intellectual 
disability. As CYP with intellectual disability are likely to 
have more severely impaired physical functioning,30 it is 
possible that CYP with intellectual disability have more 
problems completing schoolwork and more problems 
with mobility and doing usual activities. Alternatively, 
CYP without intellectual disability but with severe physical 
impairment, who will have more problems with mobility 
and doing usual activities, may also have more problems 
with completing schoolwork as a result of their physical 
impairment.
We observed an association between EQ- 5D- Y utility 
values and GMFCS level but not between CHU- 9D utility 
values and GMFCS level. Two studies reported that utility 
values obtained from the HUI-3 differed according to 
GMFCS level.26 27 However, regardless of the instrument 
used, we found that those in GMFCS levels I and II have 
a similar mean utility value, while those in GMFCS level 
III have a lower mean utility value compared with levels 
I and II. The lack of statistical evidence of an association 
between CHU- 9D utility value and GMFCS level may be 
due to the narrower utility range of the CHU- 9D, which 
resulted in smaller incremental changes between levels. 
There was also a small number of participants in GMFCS 
level III, which likely resulted in reduced statistical power 
to detect differences between groups. However, it is also 
plausible that HRQoL is not associated with functional 
mobility. When condition- specific measures of QoL were 
used, associations between QoL and GMFCS level were 
not observed.27 28
The mean EQ- 5D- Y utility value for each GMFCS level 
was similar to values obtained from the HUI-3 in one study 
(0.84, 0.50 and 0.39 for adolescents in GMFCS levels I, II 
and III, respectively)27 but not similar to those in a second 
study (0.67, 0.59 and 0.43 in GMFCS levels I, II and III, 
respectively).26 The mean CHU- 9D utility values for each 
GMFCS level were higher than those obtained from the 
HUI-3.26 27 Discrepancies may be due to differences in 
the algorithms used to derive utility values. HUI-3 utility 
values were derived in one study using preferences 
from the general adult population in Canada.27 The 
second study did not state the preferences used to derive 
HUI-3 utility values.26 Differences in utilities between 
the CHU- 9D and HUI-3 do not necessarily indicate that 
the CHU- 9D is inaccurate. The HUI-3 was only weakly 
correlated with a condition- specific measure of HRQoL 
in CYP with CP.27 This weak correlation highlights that 
condition- specific measures and generic measures of 
HRQoL may not assess similar concepts. However, unlike 
generic measures, condition- specific measures are not 
recommended for evaluations across different condi-
tions.31 Although a generic measure, the CHU- 9D may be 
more likely than the EQ- 5D- Y and HUI to capture dimen-
sions of HRQoL that are important to CYP with CP. In 
particular, the CHU- 9D includes more questions about 
psychological difficulties and pain, which are associated 
with QoL among CYP with CP.28
Limitations
The use of adult weights to value EQ- 5D- Y health states is 
a limitation of this study. It has previously been demon-
strated that values for health states ascribed by adults 
differ to corresponding health states ascribed by chil-
dren.32 33 However, we used adult weights in the absence 
of value sets for the EQ- 5D- Y. The findings of this study are 
limited by a small sample. In particular, there were a small 
number of participants in GMFCS level III. Although the 
sample included CYP with CP in GMFCS levels I- III, which 
represents about 70% of individuals with CP,34 the find-
ings may not be applicable to non- ambulatory CYP. As the 
sample volunteered to participate, they may have a higher 
HRQoL than those who did not volunteer.
In conclusion, the findings of this study illustrate that 
the EQ- 5D- Y and the CHU- 9D are feasible to use among 
CYP with CP. However, there is poor agreement between 
utility values elicited from the two instruments and they 
should not be used interchangeably to measure and 
value HRQoL in CYP with CP. This study provides further 
evidence that it is not appropriate to use the adult EQ- 5D 
tariff to derive utility values from the EQ- 5D- Y. Addition-
ally, we propose that the CHU- 9D is preferable to the 
EQ- 5D- Y for measuring HRQoL among CYP with CP 
because it was developed based on interviews with CYP, 
it assesses concepts that influence QoL among CYP with 
CP and produces less extreme values than the EQ- 5D- Y. 
However, this study is limited by a small sample size and 
more research is needed to compare these instruments in 
CYP with CP and in other clinical populations.
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